The quiet commercialization shift that's rewriting healthcare compliance
Ten years ago, if you wanted to commercialize innovation from an academic medical center, you'd wait for a promising molecule or device, negotiate a patent license, and hope for FDA approval. Today, you're negotiating for something else entirely: raw access to millions of de-identified patient records before there's even a finished product.
The AMC is no longer just curing cancer. It's also quietly exporting the data exhaust of caring for cancer, and getting paid for it.
This shift is creating massive opportunity, equally massive compliance exposure, and a set of ethical questions that nobody has convincingly answered. If you're a general counsel, chief compliance officer, or digital health founder, you can't afford to treat this as theoretical anymore. It's already happening, the regulatory scrutiny is intensifying, and the stakes are high.
Part I: How We Got Here - From Bayh-Dole to the Data Economy
For four decades, academic medicine's commercialization story was straightforward: conduct research, publish findings, patent discoveries, and license intellectual property to pharmaceutical or biotech companies once something looked translational.
This model was structurally enabled by the Bayh-Dole Act of 1980, which allowed universities and nonprofit institutions to retain ownership of inventions arising from federally funded research. Before Bayh-Dole, the federal government generally kept those rights, and commonly cited estimates suggest that only a small fraction, on the order of 5%, of government-owned patents were ever licensed. After Bayh-Dole, university tech transfer exploded. Analyses of post-Bayh-Dole technology transfer estimate that between 1996 and 2020, U.S. academic licensing activities were associated with more than 141,000 U.S. patents, over 18,000 startups, roughly $1 trillion in U.S. GDP, and $1.9 trillion in gross output, and up to 6.5 million jobs supported.[1]
In that world, "the asset" was typically a molecule, a medical device, or a surgical technique. Academic medical centers built robust technology transfer offices. They got comfortable negotiating licenses, spinning out companies, and taking equity stakes. Patients weren't directly in that economic loop - the value exchange happened after discovery, between institutions and industry.
The traditional commercialization story in academic medicine was molecule-first, data-second.
Part II: What Changed - Data Became the Product
Fast-forward to 2025. Healthcare AI models, especially in imaging, genomics, and population health, require enormous volumes of real-world clinical data to function. They don't just need a few thousand trial patients. They need years of routine care documentation for millions of people: pathology slides, radiology images, progress notes, vital signs, medications, lab results, genomic markers, treatment responses, eventual outcomes, and even social determinants of health.
Foundation models in pathology and oncology are now being trained on massive libraries of whole-slide images. Recent large-scale pathology foundation models have demonstrated specimen-level AUCs around 0.95 for common cancers and over 0.9 for many rarer cancers in pan-tumor detection tasks.[2] The core breakthrough wasn't a single drug candidate. It was access to an enormous library of digitized, labeled pathology images married to known clinical outcomes.
Industry sources report that AI development groups and data platform companies are actively purchasing or licensing de-identified electronic health record data, imaging datasets, and genomic information from hospitals and health systems. Some are aggregating data across multiple institutions into centralized products. A few are now launching national-scale genomic-plus-clinical datasets designed to be used by AI developers, covering tens of millions of patients and, in some projects, aiming for cohorts on the order of a million or more sequenced genomes.[3][4]
Translation: the AMC's raw longitudinal dataset, even before there's a finished therapy, FDA clearance, or clinical practice guideline, has become directly monetizable.
Before: You license a drug once you prove it works.
Now: You license the data exhaust of care itself, because AI can turn that exhaust into a product.
Part III: How These Deals Actually Look in Practice
Let's walk through a hypothetical structure based on arrangements we're seeing in the market.
The Asset Being Licensed
A large nonprofit academic medical center controls a massive internal clinical data warehouse containing decades of inpatient and outpatient encounters: labs, diagnoses, vital signs, pathology reports, operative notes, treatment plans, medication histories, imaging studies, and long-term outcomes. The data is continuously refreshed and harmonized so each patient's clinical journey can be tracked longitudinally.
Before this data leaves the institution's control, it must be de-identified. De-identification is typically accomplished through one of two HIPAA-compliant methods:
Safe Harbor Method: Removal of the 18 direct identifiers specified in federal regulations (name, Social Security number, medical record number, full address, dates more specific than year, etc.)
Expert Determination: A qualified statistician certifies that the risk of re-identification is "very small," sometimes after applying additional protections like date-shifting, geographic generalization, or data perturbation.[5]
Critically, the for-profit partner does not simply download raw protected health information. In many structures, data can only be accessed within a locked-down Secure Access Portal - a controlled computing environment hosted and monitored by the AMC or its affiliate. This environment features:
- Role-based access controls
- Comprehensive audit trails
- Two-factor authentication
- Technical safeguards preventing unauthorized downloading or exporting
- Administrative and physical security measures
Governance and Approvals
Nothing moves forward without pre-clearance from the AMC's internal governing body. Typical requirements include:
- Institutional Review Board (IRB) approval where human-subjects research is implicated
- Written authorization from AMC leadership, especially when publication or external collaboration is contemplated
- Reputational veto rights: Agreements often explicitly state that the AMC can reject any study reasonably expected to "reflect negatively on the quality of care, doctors, relationships, or operations" of the health system
This isn't just bureaucracy. It's liability management. Academic medical centers are protecting their clinical reputation, their research integrity, and their nonprofit status.
Use Restrictions
The commercial partner faces strict contractual prohibitions:
- No re-identification attempts: The partner cannot try to identify any individual patient or their family members, directly or indirectly
- No patient contact: Even if re-identification occurs accidentally, contacting patients is forbidden
- Immediate breach notification: If residual protected health information is discovered, the AMC must be notified within a defined time window (e.g., 48 hours)
- Data destruction: Upon termination of the agreement, all data must be destroyed and certified destroyed, with limited exceptions for legally required retention
Economic Structure and Fair Market Value
Early-stage data collaborations are often structured as cost recovery only: the for-profit partner reimburses the AMC for the actual cost of data extraction, cleaning, standardization, statistical de-identification, and secure infrastructure, plus reasonable overhead. At this stage, there's no "license royalty," which helps the AMC defend that it's neither giving away charitable assets below value nor profiteering from protected health information.
Later, once a specific commercial use case is defined, for example, a validated algorithm, a decision-support tool, or a data product to be sold to pharmaceutical companies or payers, the parties negotiate a formal data license agreement. This later-stage license typically includes:
- Defined scope: Specific data elements, refresh cadence, permitted indications
- Commercialization rights: What the licensee can build and sell using the data
- Economic arrangement priced to fair market value
Fair market value assessments for data access typically employ multiple methodologies:
- Income Approach: Calculating the incremental commercial value attributable to having access to the data versus not having access, applying market-based royalty rates, and discounting future value to present terms
- Market Approach: Referencing comparable transactions for similar data types, considering factors like record volume, data richness, longitudinal depth, and permitted use cases
- Cost Approach: In some cases, documenting the replacement cost of assembling comparable data infrastructure and capture capabilities
The key point: these aren't token payments. Large-scale clinical datasets from major AMCs can command substantial fair market valuations, and those valuations must be defensible to regulators and tax authorities.[6]
Updates and Continuity
Many agreements provide for quarterly data updates, with each refresh coded to enable longitudinal tracking of individual patient records over time (while maintaining de-identification). This creates a continuous data pipeline rather than a one-time snapshot, dramatically increasing utility for AI model training and validation.
Part IV: The Nonprofit Compliance Problem Nobody's Taking Seriously Enough
Here's where most institutions are dangerously exposed.
501(c)(3) tax-exempt hospitals and academic medical centers are subject to intermediate sanctions regulations. These rules prohibit "excess benefit transactions" - arrangements where a nonprofit provides an economic benefit to a "disqualified person" (including officers, directors, substantial contributors, or related entities) for less than fair market value. Under IRS guidance, that analysis explicitly applies to economic benefits like the use of property and intangible assets, not just cash compensation.[7] In practice, that means data access rights sit in the same FMV bucket as any other asset the nonprofit is allowing insiders or related for-profit entities to use.
If a nonprofit AMC gives a for-profit AI company access to decades of clinical data for free or below-market rates, that can constitute private inurement, especially if any AMC insiders have financial interests in the for-profit entity.
To stay on the right side of intermediate-sanctions rules, general counsel and CFOs should treat data access like any other FMV-sensitive benefit: document fair market value contemporaneously, using recognized valuation methods, and refresh it as the scope of use or dataset grows. In other words, data-sharing deals belong in the same FMV documentation stack as:
- Physician compensation arrangements
- Joint venture distributions
- Call coverage agreements
- Medical director contracts
- Any other transaction with referral or regulatory sensitivity
You can't just "believe in the mission" and hand over data. You have to prove you didn't transfer public-benefit assets below fair market value.
This requires:
- Independent valuation: Engage qualified professionals to assess FMV using recognized methodologies (income approach, market approach, cost approach)
- Contemporaneous documentation: Valuation should occur at or near the time of the transaction, not years later during an audit
- Reasonable economic structure: The compensation must reflect what unrelated parties would pay in arm's-length negotiations
- Ongoing reassessment: As data volumes grow or commercial applications evolve, FMV should be revisited
Part V: The Privacy and Ethics Problem Nobody Has Solved
Here's the uncomfortable truth: HIPAA's de-identification standard was designed in an early-2000s, pre-foundation-model world, not for 2025-era multimodal AI.
The Safe Harbor method treats data as de-identified for HIPAA purposes once 18 specific identifiers are removed (names, full addresses, dates more specific than year, Social Security numbers, medical record numbers, etc.). The law assumes that if you strip out those identifiers, the remaining data is no longer "individually identifiable" health information. The Expert Determination method relies on a statistician's judgment that the risk of re-identification is "very small," often based on today's linkage and attack models.[5]
Modern AI breaks those assumptions.
Studies have demonstrated that combining de-identified genetic data with certain publicly available information can enable re-identification of individuals or families. Researchers have also raised concerns that large language models trained on clinical narratives may be able to infer sensitive attributes or identities even after explicit identifiers are removed, particularly when models are fine-tuned or combined with other datasets.[8]
If pooled de-identified data plus high-capability AI models can effectively infer who you are, is the hospital really protecting patients, or just complying with a paperwork standard?
State regulators are paying attention. California has enacted both the California Consumer Privacy Act (as amended by the CPRA) and the California Delete Act (SB 362), which together give consumers broad rights to opt out of data sales and demand deletion of their data from data brokers, including, by 2026, via a single "one-stop" deletion mechanism covering registered data brokers.[9]
State attorneys general have already scrutinized transactions involving large genetic datasets, particularly where:
- Original consent forms didn't explicitly contemplate commercial AI model training or broad data sharing
- There was no clear mechanism for patients to later withdraw their data
- Economic benefits flowed primarily to companies rather than patients or the health system[10]
And then there's the question patients will increasingly ask: "If both the hospital and the AI company are making money off my tumor slides, why don't I?"
Industry observers and ethicists are floating benefit-sharing models that would give patients:
- Direct financial compensation for data use
- Equity stakes in companies built on their data
- "Data dividends" distributed across patient populations
- At minimum, transparent disclosure about commercial data use and the ability to opt out
No consensus model has emerged yet. But regulatory pressure, media scrutiny, and patient advocacy are all moving in one direction: toward greater accountability for who benefits when clinical data becomes a commercial product.
Part VI: What Leadership Teams Should Do Right Now
For Academic Medical Centers
- Treat data like any other regulated asset. Put data licensing under the same governance you use for referral-sensitive deals: a formal committee, written policies for external sharing, and board-level review for material arrangements.
- Document fair market value like you mean it. Require independent FMV support for all commercial data access (including "research collaborations" that look commercial), document assumptions contemporaneously, and refresh valuations as scope or volume grows.
- Harden the pipes and fix the paperwork. Favor secure access environments over bulk exports, with audit trails and contractual bans on re-identification. At the same time, modernize consent and notice language, offer meaningful opt-out where feasible, and be explicit about what can and cannot be unwound once data is de-identified and distributed.
- Own the story. Be clear with boards, clinicians, and communities about what you're doing, why, and who benefits. If you can't explain that in a single slide without euphemisms, you're not ready to sign the deal.
For AI Companies and Digital Health Founders
- Assume hospital governance is real. Build time and budget for IRB-style oversight, data-use committees, and compliance documentation, even when you think you're "just" doing product development.
- Price and paper data access to FMV. Don't treat hospital data like a loss leader or an informal favor. Use valuation professionals, align economics with arm's-length expectations, and help your nonprofit partners defend the deal on FMV grounds.
- Design around privacy, re-identification, and benefit-sharing. Operate as if re-identification risk is a live regulatory grenade, not a theoretical edge case. Build technical and policy safeguards against it, and be prepared to show how patients and health systems actually benefit—whether through better outcomes, lower costs, or explicit benefit-sharing mechanisms.
Conclusion: The New Reality
Academic medical centers have spent decades building world-class technology transfer operations. They know how to protect IP, negotiate licenses, and manage conflicts of interest around inventions. But data commercialization is different.
Data is continuous, not discrete. It's generated through the course of clinical care, not through discrete research projects. Its value compounds over time. And critically, it comes directly from patients, who never signed up to be unpaid contributors to a commercial AI training dataset.
The legal, ethical, and reputational complexity of data licensing is at least as high as traditional tech transfer, but most institutions are applying far less rigor.
If you're a general counsel, chief compliance officer, chief data officer, or digital health founder, here's the bottom line: assume this will be regulated, litigated, and politicized, and build your governance, pricing, and ethics accordingly.
The institutions and companies that get ahead of this will define best practices. The ones that don't will define cautionary tales.
The choice is yours.
Notes
[1] Ashley J. Stevens et al., The Economic Contributions of University/Nonprofit Inventions in the United States: 1996–2020 (Biotechnology Innovation Organization, AUTM, and IPO, 2024).
[2] Paige, "Q&A: David Klimstra on Virchow, the World's Largest Pathology Foundation Model," Paige.ai blog, 2024, and related Virchow foundation model publications reporting multi-cancer whole-slide image AUCs.
[3] Truveta, "Data Platform" and "Truveta Studio" product descriptions (accessed 2025), describing a de-identified EHR dataset covering more than 120 million patients.
[4] National Institutes of Health, "All of Us Research Program Overview" and "Program Goals" (accessed 2025), and similar large-scale genomics initiatives describing cohorts of one million or more participants with genomic and EHR data.
[5] U.S. Department of Health and Human Services, Office for Civil Rights, "Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the HIPAA Privacy Rule," November 26, 2012.
[6] Discussion of valuation approaches is based on standard income, market, and cost approach methodologies used in health care valuation practice and guidance from professional bodies such as the ASA and NACVA.
[7] Internal Revenue Service, "Intermediate Sanctions – Excess Benefit Transactions" (IRC §4958) and related IRS training materials describing economic benefits including use of property and intangible rights.
[8] Yaniv Erlich and Arvind Narayanan, "Routes for Breaching and Protecting Genetic Privacy," Nature Reviews Genetics 15 (2014): 409–421; Melissa Gymrek et al., "Identifying Personal Genomes by Surname Inference," Science 339 (2013): 321–324.
[9] California Department of Justice, summaries of the California Consumer Privacy Act (CCPA/CPRA); and California Delete Act (SB 362), codified at Cal. Civ. Code §1798.99.80 et seq., establishing a one-stop deletion mechanism for registered data brokers.
[10] Press releases and public statements by state attorneys general regarding scrutiny of large genetic datasets and proposed sales of consumer genetic data, including actions related to companies like 23andMe.